About Us | Contact

Dr. Nathan Bahary Investigator

West Penn Hospital NPI1578535803
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$32,690.80
from 50 payments in the last 6 years

Total Cash or Cash Equivalent

$26,684.02
from 18 payments in the last 6 years

Total In-kind Items & Services

$6,006.78
from 32 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
01/24/2020 General (Non-Research) In-kind items and services Food and Beverage $45.81 Details
Payment from Genentech, Inc.
Payment Record ID 743071707
06/30/2020 Research In-kind items and services Biological $1003.06 Details
Payment from F. Hoffmann-La Roche AG
Paymment Research Study A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER MORPHEUS-LUNG, A PHASE IbII, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA MORPHEUS-PANCREATIC CANCER, A PHASE IbII, OPEN-LABEL
Payment Record ID 742987227
11/21/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $2740.00 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 735814887
01/19/2018 General (Non-Research) In-kind items and services Food and Beverage $44.04 Details
Payment from Genentech, Inc.
Payment Record ID 708825711
06/20/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $14.79 Details
Payment from Exelixis Inc.
Payment Record ID 686556541
06/20/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $23.00 Details
Payment from Exelixis Inc.
Payment Record ID 686556539
06/21/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $104.73 Details
Payment from Exelixis Inc.
Payment Record ID 686556537
06/21/2019 General (Non-Research) In-kind items and services Travel and Lodging $270.07 Details
Payment from Exelixis Inc.
Payment Record ID 686556535
04/26/2019 General (Non-Research) In-kind items and services Travel and Lodging $508.80 Details
Payment from Exelixis Inc.
Payment Record ID 686556533
06/21/2019 General (Non-Research) In-kind items and services Food and Beverage $74.65 Details
Payment from Exelixis Inc.
Payment Record ID 686556531
06/21/2019 General (Non-Research) In-kind items and services Food and Beverage $39.99 Details
Payment from Exelixis Inc.
Payment Record ID 686556529
06/12/2019 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2500.00 Details
Payment from Exelixis Inc.
Payment Record ID 686556527
09/23/2019 General (Non-Research) In-kind items and services Food and Beverage $92.38 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685919043
01/22/2019 Research Cash or cash equivalent $11243.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER
Clinical Trials Gov ID NCT03086369
Payment Record ID 654283821
04/25/2019 Research In-kind items and services Drug $741.85 Details
Payment from Eli Lilly and Company
Paymment Research Study RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE -BSC- VERSUS PLACEBO AND BSC AS SECOND-LINE TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN -AFP- FOLLOWING FIRST LINE THERAPY WITH SORAFENIB
Clinical Trials Gov ID NCT02435433
Payment Record ID 654283819
06/25/2019 Research In-kind items and services $105.60 Details
Payment from Eli Lilly and Company
Paymment Research Study RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN
Clinical Trials Gov ID NCT02923921
Payment Record ID 654283613
12/11/2018 Research Cash or cash equivalent $2145.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER
Clinical Trials Gov ID NCT03086369
Payment Record ID 585604349
01/18/2018 General (Non-Research) Cash or cash equivalent Food and Beverage $114.13 Details
Payment from E.R. Squibb & Sons, L.L.C.
Payment Record ID 572169775
01/18/2018 General (Non-Research) Cash or cash equivalent Food and Beverage $6.32 Details
Payment from E.R. Squibb & Sons, L.L.C.
Payment Record ID 572169773
01/26/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $1704.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Payment Record ID 572169771
04/17/2018 General (Non-Research) Cash or cash equivalent Food and Beverage $10.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Payment Record ID 572169769
04/20/2018 General (Non-Research) In-kind items and services Food and Beverage $42.50 Details
Payment from Exelixis Inc.
Payment Record ID 566894961
04/20/2018 General (Non-Research) In-kind items and services Food and Beverage $72.50 Details
Payment from Exelixis Inc.
Payment Record ID 566894203
05/02/2018 General (Non-Research) Cash or cash equivalent Travel and Lodging $129.09 Details
Payment from Exelixis Inc.
Payment Record ID 566892987
04/20/2018 General (Non-Research) In-kind items and services Travel and Lodging $297.00 Details
Payment from Exelixis Inc.
Payment Record ID 566892071
04/20/2018 General (Non-Research) In-kind items and services Travel and Lodging $374.20 Details
Payment from Exelixis Inc.
Payment Record ID 566891845
04/20/2018 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2400.00 Details
Payment from Exelixis Inc.
Payment Record ID 566890837
06/03/2018 General (Non-Research) In-kind items and services Food and Beverage $132.61 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 561801059
03/28/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $500.00 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 561081248
10/02/2017 General (Non-Research) In-kind items and services Travel and Lodging $21.18 Details
Payment from Halozyme Inc
Payment Record ID 506402691
10/02/2017 General (Non-Research) In-kind items and services Food and Beverage $44.06 Details
Payment from Halozyme Inc
Payment Record ID 506402685
10/02/2017 General (Non-Research) In-kind items and services Travel and Lodging $263.52 Details
Payment from Halozyme Inc
Payment Record ID 506402679
09/16/2017 General (Non-Research) In-kind items and services Food and Beverage $27.05 Details
Payment from Halozyme Inc
Payment Record ID 506402569
09/16/2017 General (Non-Research) In-kind items and services Food and Beverage $50.00 Details
Payment from Halozyme Inc
Payment Record ID 506402444
09/16/2017 General (Non-Research) In-kind items and services Food and Beverage $50.00 Details
Payment from Halozyme Inc
Payment Record ID 506402441
09/16/2017 General (Non-Research) In-kind items and services Food and Beverage $55.09 Details
Payment from Halozyme Inc
Payment Record ID 506402354
09/16/2017 General (Non-Research) In-kind items and services Travel and Lodging $70.00 Details
Payment from Halozyme Inc
Payment Record ID 506402333
09/16/2017 General (Non-Research) In-kind items and services Travel and Lodging $455.72 Details
Payment from Halozyme Inc
Payment Record ID 506402173
09/15/2017 General (Non-Research) In-kind items and services Food and Beverage $2.82 Details
Payment from Halozyme Inc
Payment Record ID 506402099
09/15/2017 General (Non-Research) In-kind items and services Food and Beverage $125.00 Details
Payment from Halozyme Inc
Payment Record ID 506402043
06/14/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $2500.00 Details
Payment from Celgene Corporation
Payment Record ID 501647983
06/01/2017 General (Non-Research) In-kind items and services Travel and Lodging $268.80 Details
Payment from Celgene Corporation
Payment Record ID 501647979
06/01/2017 General (Non-Research) In-kind items and services Food and Beverage $116.83 Details
Payment from Celgene Corporation
Payment Record ID 501647973
09/26/2017 Research In-kind items and services $475.20 Details
Payment from Eli Lilly and Company
Paymment Research Study AN ADAPTIVE, OPEN-LABEL, RANDOMIZED PHASE 2 STUDY OF ABEMACICLIB AS A MONOTHERAPY AND IN COMBINATION WITH OTHER AGENTS VERSUS CHOICE OF STANDARD OF CARE (GEMCITABINE OR CAPECITABINE) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical Trials Gov ID NCT02981342
Payment Record ID 457098153
06/22/2016 General (Non-Research) Cash or cash equivalent Travel and Lodging $24.00 Details
Payment from Halozyme Inc
Payment Record ID 376149522
06/22/2016 General (Non-Research) Cash or cash equivalent Travel and Lodging $23.76 Details
Payment from Halozyme Inc
Payment Record ID 376149482
06/22/2016 General (Non-Research) In-kind items and services Food and Beverage $26.90 Details
Payment from Halozyme Inc
Payment Record ID 376149442
06/22/2016 General (Non-Research) In-kind items and services Food and Beverage $25.87 Details
Payment from Halozyme Inc
Payment Record ID 376149392
06/22/2016 General (Non-Research) In-kind items and services Food and Beverage $83.68 Details
Payment from Halozyme Inc
Payment Record ID 376149354
06/22/2016 General (Non-Research) Cash or cash equivalent Travel and Lodging $502.20 Details
Payment from Halozyme Inc
Payment Record ID 376149316
;